Hot Investor Mandate: Cross-Border Investment Firm with USA and China Offices Invests Up to $10M in Life Science Companies in North America

20 Jun

A private investment firm with offices in USA and China consists of limited partners who include institutional investors from US and China. Typical equity investments range from US$5-10 million in businesses from Series A to pre-IPO and publicly traded companies. The firm is open to leading or following a syndicated round. Good Health Capital is now focusing on opportunities in North America.

The firm invests across therapeutics, medical devices, diagnostics, platform technologies, and digital health and is looking for companies that are top 3 in their niche sector. Within therapeutics, the firm prefer clinical stage projects. The firm is opportunistic in terms of disease areas including orphan indications. Within device and diagnostics, the firm prefers post-prototype products with clinical validation.

The firm may request board representation or board observership on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: